- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Doctronic Raises $40 Million for AI-Powered Prescription Renewal Platform
The healthcare startup's Series B funding will expand partnerships and push into pediatric care.
Mar. 30, 2026 at 6:18pm
Got story updates? Submit your updates here. ›
Doctronic, a New York-based healthcare technology company, has raised $40 million in a Series B funding round co-led by Abstract and Lightspeed Venture Partners. The financing brings Doctronic's total funding to over $65 million and will be used to expand partnerships with health systems, payers, and digital health platforms, as well as support a push into pediatric care.
Why it matters
Doctronic's AI-powered platform is designed to autonomously evaluate symptoms, generate diagnoses, and guide treatment decisions, including the ability to renew prescriptions without human intervention. This innovative approach aims to improve healthcare access and outcomes at scale, addressing the growing demand for primary care services.
The details
Founded in 2023 by Adam Oskowitz and Matt Pavelle, Doctronic became the first AI-native platform authorized to autonomously renew prescriptions in the United States under Utah's AI Learning Lab regulatory sandbox. The platform currently supports prescription renewals across 190 medications and includes safeguards such as continuous monitoring and automatic escalation to licensed physicians for complex cases. Doctronic operates its own clinical practice, licensed across all 50 states, and integrates with national health data networks to access patient records, medication histories, and drug interaction data.
- Doctronic announced the $40 million Series B funding round on March 30, 2026.
- In December 2025, Doctronic became the first AI-native platform authorized to autonomously renew prescriptions in the United States under Utah's AI Learning Lab regulatory sandbox.
The players
Doctronic
A New York-based healthcare technology company that has built an AI-powered clinical system designed to autonomously evaluate symptoms, generate diagnoses, and guide treatment decisions.
Adam Oskowitz
Co-founder of Doctronic.
Matt Pavelle
Co-founder and Co-CEO of Doctronic.
Abstract
A venture capital firm that co-led Doctronic's Series B funding round.
Lightspeed Venture Partners
A venture capital firm that co-led Doctronic's Series B funding round.
What they’re saying
“Doctronic proved what we believed from the start: AI can deliver better healthcare outcomes at scale. The Utah program validated their clinical rigor. The revenue growth validated market demand. What sets them apart is the courage to take responsibility for outcomes, not just provide information. That's the future of healthcare.”
— Ramtin Naimi, Partner at Abstract
“The combination of user traction, revenue momentum, and partnerships with major health systems makes it clear: Doctronic is the breakout leader in AI-powered medicine. They've built autonomous AI that integrates safely into real clinical workflows and brings in real patient context, uniquely delivering on the treatment through triage vision at an unmatched scale.”
— Faraz Fatemi, Partner at Lightspeed Venture Partners
“This round reflects Doctronic's category leadership: unmatched consumer scale and a best-in-class AI clinical model. Health systems see us as infrastructure, the digital front door that routes their patients efficiently and keeps care in-network. Payers see us as unlimited primary care at predictable cost. This round lets us push further into academic medical centers, digital health platforms, and payers, while continuing to serve millions of consumers directly.”
— Matt Pavelle, Co-CEO and Co-Founder of Doctronic
“We're not just faster and cheaper than traditional care, we're more thorough. Our AI performs dozens of safety checks per prescription renewal that would take a human physician an hour. The 99.2% treatment alignment rate isn't theoretical, it's from real patients in real clinical scenarios. But what I'm most proud of is retention. Since the Series A, monthly repeat physician visits have nearly tripled. Patients aren't just trying us, they're coming back.”
— Adam Oskowitz, Co-Founder of Doctronic
What’s next
Doctronic is in discussions with regulators in additional states and international markets to expand its AI-driven prescription capabilities.
The takeaway
Doctronic's AI-powered platform represents a new model for delivering primary care at scale, offering 24/7 access to AI-driven consultations and optional telehealth visits with licensed physicians. The company's ability to take responsibility for clinical outcomes, rather than just providing informational support, positions it as a leader in the evolution of AI in healthcare.
